Bioventus, Inc. (BVS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$13.63-1.45%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Bioventus grows revenue about 8% yearly, with 2026 guidance at $600M-$610M. Profit per share is expected near $0.77, raised recently. Cash from operations guidance was raised to $84M-$89M, showing improving cash flow. The company trades cheaply versus peers with a PE of 15.3 versus 36.5.
Revenue declined 16% from Q4 2025 to Q1 2026, signaling demand weakness. Cash from operations fell sharply in Q1 2026 to $8.9M from $38M prior quarter. Profit margins and growth may soften if these trends continue.
The price is about 38% below our fair value near $18. Analysts expect about 8% revenue growth. Our view aligns with this but sees risk if revenue and cash flow weaken further.
Breaks if: Adjusted EPS falls below $0.75 in FY26
Management is raising full-year 2026 guidance for Adjusted EPS and Cash from Operations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity in the healthcare sector. BVS is currently navigating through a period of strong financial performance while focusing on advancing its Pain Treatments segment.
The market appears to have a neutral valuation on BVS, with a slight expectation gap indicating that it is priced reasonably compared to peers. There is a low fragility tier, suggesting that the current market conditions do not imply significant vulnerabilities.
BVS is expected to continue its revenue growth trajectory, supported by management's reaffirmed guidance. However, the elevated risk level and recent litigation could pose challenges that need monitoring.
The long-term thesis hinges on BVS's ability to maintain its financial guidance and the performance of key sector bellwethers. Additionally, any cuts to guidance or worsening economic indicators could negatively impact the stock.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Cash from operations falls below $84 million in FY26
Management is raising full-year 2026 guidance for Adjusted EPS and Cash from Operations.
Breaks if: Revenue falls below $600 million in FY26
Breaks if: PE ratio rises above 36.5
Overall, BVS's fundamentals remain intact, but investors should watch for developments in guidance and sector performance. Not investment advice.